Evidence map›Paper›PMID 39459868›Full record

ArticleViruses2024

COVID-19 in Relation to Polypharmacy and Immunization (2020-2024).

Anna Puigdellívol-Sánchez, Marta Juanes-González, Ana Calderón-Valdiviezo, Roger Valls-Foix, Marta González-Salvador, Celia Lozano-Paz, Josep Vidal-Alaball

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04367883 recruitingnot on this map

Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection

TypeobservationalSponsorConsorci Sanitari de TerrassaRan2020 to 2028Enrolled3,000ConditionsCOVID19, Influenza Vaccination, ACE Inhibitors, ARBArmsAntihistamine, Amantadine, ACEI, ARB, Influenza vaccine and COVID
NCT05504057 recruitingnot on this map

Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

TypeobservationalSponsorConsorci Sanitari de TerrassaRan2020 to 2028Enrolled140,660ConditionsCOVID-19ArmsAntihistamine, Amantadine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna Puigdellívol-SánchezMedicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.ORCID 0000-0001-7239-2953
Marta Juanes-GonzálezMedicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.ORCID 0000-0002-8682-6000
Ana Calderón-ValdiviezoMedicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.
Roger Valls-FoixMedicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.ORCID 0000-0002-1016-4039
Marta González-SalvadorManagement, Control and Information Analysis Unit, Hospital Universitari de Terrassa, Consorci Sanitari de Terrassa, Carretera de Torrebonica s/n, 08227 Terrassa, Spain.
Celia Lozano-PazMedicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.ORCID 0000-0003-2301-2509
Josep Vidal-AlaballIntelligence for Primary Care Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina, c/ Soler i March 6, 08242 Manresa, Spain.ORCID 0000-0002-3527-4242

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObservational studies reported worse COVID-19 evolution in relation to polypharmacy and reductions in COVID-19 hospital admissions and death in patients receiving chronic antihistamine treatment. The current profile of hospitalized patients with regard to different variants was analyzed to identify specific targets for future prospective trials.

methodsCOVID-19 admissions to the Hospital of Terrassa (11 March 2020-28 August 2024 (n = 1457), from the integral Consorci Sanitari de Terrassa population (n = 167,386 people) were studied. Age, gender, the number of chronic treatments (nT), and immunization status were analyzed.

resultsAfter 5 May 2023, 291 patients (54% females) required COVID hospitalization. Of these, 39% received >8 nT (23% receiving 5-7 nT), 70.2% were >70 years, and 93.4% survived. In total, 12% of patients admitted after 5 May 2024 were not vaccinated, while 59% received ≥4 vaccines (43% within the last 12 months). In total, 49% of admitted patients presented no previous infection (while 3% presented infection during the last year). Delta or Omicron variants would have accounted for ≥80% of admissions > 60 years compared to the first pandemic wave if no vaccines existed.

conclusionsPatients > 70 years who receive ≥5 nT, without prior COVID-19 infections, should be the priority for prevention, with updated vaccination and early treatments to reduce hospitalizations.

Indexed as

COVID-19HospitalizationPolypharmacySARS-CoV-2AdultAgedAged, 80 and overCOVID-19 VaccinesFemaleHumansImmunizationMaleMiddle AgedVaccinationYoung AdultCOVID-19 VaccinesCOVID-19death ratehospital admissionpolypharmacyvaccination

Identifiers

PMID39459868
PMCPMC11512247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.